Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fentanyl transdermal - Hisamitsu

Drug Profile

Fentanyl transdermal - Hisamitsu

Alternative Names: Fentanyl citrate patch - Hisamitsu; Fentanyl citrate transdermal - Hisamitsu; FENTOS; FENTOS TAPE; FENTOS® TAPE; HFT-290

Latest Information Update: 15 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hisamitsu Pharmaceutical
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Pain

Most Recent Events

  • 02 Jul 2018 Launched for Cancer pain in Japan (Transdermal, 0.5mg)
  • 02 Jul 2018 Launched for Pain in Japan (Transdermal, 0.5mg)
  • 02 Jul 2018 Registered for Pain in Japan (Transdermal 0.5 mg)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top